However, some of the CFC-associated MEK mutations confer resistance to the MEK inhibitor trametinib (Emery et al., 2017), indicating that MEK inhibitors may not always be appropriate therapeutics for patients with MEK-associated CFC, despite the preclinical finding that elongated zebrafish embryos, a phenotype caused by expression of map2k1Y130C, can be reversed by the MEK inhibitors CI-1040 and PD-0325901 (Anastasaki et al., 2009). The gene discussed is MAP2K7; the disease is cardiofaciocutaneous syndrome.